secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2026-05-13T20:15:17+00:00
Accession:  0001193125-26-221658
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon Q1 net loss $39M; cash $111.1M; 100% insulin independence in islet trial
-------------------------------------------------------------------------------

- Cash, equivalents and short-term investments $111.1M as of March 31, 2026, down from $133.3M at Dec 31, 2025; funding expected into Q2 2027.
- Net loss $39.0M ($0.33/share) vs $6.5M ($0.08/share) in Q1 2025; includes $19M non-cash loss from warrant liabilities.
- R&D expense $17.2M (incl. $1.1M stock comp) vs $13.5M in prior year; G&A $4.0M vs $4.4M.
- 10/10 evaluable patients achieved 100% insulin independence with tegoprubart in islet transplantation; no rejection or tacrolimus-like toxicities.
- FDA granted Orphan Drug designation for tegoprubart in liver transplantation; Phase 3 kidney trial design guidance expected from FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000119312526221658/0001193125-26-221658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000119312526221658/eldn-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-221658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer